FDA approves generic nocturnal enuresis agent

August 1, 2005

Barr Laboratories, Inc. has received FDA approval to market a generic version of desmopressin acetate tablets in 0.1- and 0.2-mg strengths. The agent is indicated for the treatment of primary nocturnal enuresis.

Barr Laboratories, Inc. has received FDA approval to market a generic version of desmopressin acetate tablets in 0.1- and 0.2-mg strengths. The agent is indicated for the treatment of primary nocturnal enuresis.

For more information, call 201-930-3303 or 800-222-0190, or visit www.barlabs.com.